AstraZeneca’s COVID-19 vaccine

 U.K. regulator granted emergency use authorisation of AstraZenca's Vaccine on 30.12.20 

It is based on weakened Adenovirus, i.e. a common cold flu virus  which contains genetic material of spike protein.

Can be stored and transported at 2°- 8°.

less costly then mRNA Vaccines like that of Pfizer and Moderna.

Showed 62% efficacy when 2 full strength dose administered 4 weeks apart, as per published report.


Comments

Popular posts from this blog

Earth's rotational speed

The “Chandler Wobble”